225Ac/89Zr标记的N4MU01放射免疫偶联物作为靶向Nectin-4阳性三阴性乳腺癌的诊疗一体化药物
研究以全人源抗Nectin-4抗体N4MU01构建89Zr和225Ac放射免疫偶联物,在三阴性乳腺癌(TNBC)异种移植和同种移植模型中评估成像与治疗效果。结果显示[89Zr]Zr-DFO-N4MU01在MDA-MB-468荷瘤小鼠120小时肿瘤摄取达13.2 ± 1.12 %ID/g,[225Ac]Ac-Macropa-N4MU01在MDA-MB-468和4T1.nectin-4荷瘤小鼠中分别实现100%(6/6)和83.3%(5/6)完全肿瘤缓解。作者认为其特异性肿瘤摄取和对侵袭性TNBC的显著疗效很有前景,值得开展临床开发。
要点
- Nectin-4在60%-70%的TNBC中过表达,是放疗和PET成像的理想靶点。
- [89Zr]Zr-DFO-N4MU01在MDA-MB-468荷瘤小鼠120小时肿瘤摄取为13.2 ± 1.12 %ID/g。
- [225Ac]Ac-Macropa-N4MU01在MDA-MB-468和4T1.nectin-4荷瘤小鼠中分别实现100%(6/6)和83.3%(5/6)完全肿瘤缓解。
核心结论
- 作者认为N4MU01放射免疫偶联物对侵袭性TNBC肿瘤的特异性摄取和显著疗效非常有前景,值得开展临床开发。
研究设计与样本
- 研究使用全人源抗Nectin-4抗体N4MU01,分别以89Zr和225Ac标记用于成像和放疗,在TNBC异种移植和同种移植模型中评估。
- 在荷Nectin-4阳性异种移植瘤小鼠中研究[89Zr]Zr-DFO-N4MU01的生物分布和PET成像。
- 在naïve BALB/c小鼠中研究[225Ac]Ac-Macropa-N4MU01的剂量学和毒性。
- 在荷人TNBC MDA-MB-468异种移植瘤或人Nectin-4转染4T1(4T1.nectin-4)同种异体移植瘤的athymic BALB/c nude小鼠中,以13 kBq或18.6 kBq的两剂方案(间隔10天给药)评估疗效。
主要发现
- [89Zr]Zr-DFO-N4MU01的药代动力学呈双相分布,中等消除半衰期为63小时。
- [89Zr]Zr-DFO-N4MU01在荷MDA-MB-468异种移植瘤小鼠中120小时肿瘤摄取高,为13.2 ± 1.12 %ID/g。
- [225Ac]Ac-Macropa-N4MU01在MDA-MB-468细胞中有效内化,对细胞有毒性,50%抑制浓度为1.2 kBq/mL。
- 毒性研究显示15 kBq的[225Ac]Ac-Macropa-N4MU01总体耐受良好,血液学、血液生化学和组织病理学分析支持这一结论。
- 荷MDA-MB-468和4T1.nectin-4异种移植瘤小鼠接受13 kBq [225Ac]Ac-Macropa-N4MU01治疗后,分别有100%(6/6)和83.3%(5/6)完全肿瘤缓解。
局限性
- 作者在结论中提出该结果非常有前景并值得开展N4MU01放射免疫偶联物的临床开发,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nectin-4 is an overexpressed biomarker in 60%-70% of triple-negative breast cancer (TNBC) cases and an ideal target for radiotherapy and PET imaging. In this study, theranostic radioimmunoconjugates were developed using a fully human anti-nectin-4 antibody (N4MU01). The imaging properties and therapeutic effectiveness of the radioimmunoconjugates were evaluated using TNBC models. Methods: N4MU01 was radiolabeled with 89Zr and 225Ac for imaging and radiotherapy, respectively, using TNBC xenograft and syngeneic models. Biodistribution and PET imaging of the [89Zr]Zr-deferoxamine (DFO)-N4MU01 radioimmunoconjugate was studied in mice bearing nectin-4-positive xenografts. Dosimetry and toxicity of [225Ac]Ac-Macropa-N4MU01 were studied in naïve BALB/c mice, and the therapeutic efficacy was evaluated with two doses of 13 or two doses of 18.6 kBq, administered 10 d apart in athymic BALB/c nude mice bearing either a human TNBC MDA-MB-468 xenograft or a human nectin-4-transfected 4T1 (4T1.nectin-4) syngeneic allograft. Results: The pharmacokinetic profile of the [89Zr]Zr-DFO-N4MU01 radioimmunoconjugate showed biphasic distribution with a moderate elimination half-life of 63 h. PET imaging and biodistribution of [89Zr]Zr-DFO-N4MU01 in mice bearing the MDA-MB-468 xenograft showed high tumor uptake of 13.2 ± 1.12 percent injected activity per gram at 120 h. [225Ac]Ac-Macropa-N4MU01 was effectively internalized in MDA-MB-468 and was cytotoxic to the cells with a 50% inhibition concentration of 1.2 kBq/mL. Toxicity studies revealed that 15 kBq of [225Ac]Ac-Macropa-N4MU01 was generally well tolerated, as indicated by hematologic, blood chemistry, and histopathologic analysis. Mice bearing MDA-MB-468 and 4T1.nectin-4 xenografts treated with 13 kBq of [225Ac]Ac-Macropa-N4MU01 had 100% (6/6) and 83.3% (5/6) complete tumor remissions, respectively. Conclusion: The specific tumor uptake and remarkable effectiveness against aggressive TNBC tumors are very promising and warrant the clinical development of N4MU01 radioimmunoconjugates.
引用
- Babeker H, Njotu FN, Pougoue Ketchemen J, et al. 225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer. J Nucl Med. 2025. PMID: 39978811. doi:10.2967/jnumed.124.268387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。